Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-89853413 in Relapsed or Refractory AML or MDS
NCT06618001Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of JNJ-89853413 in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events at 2.5 years and Dose-Limiting Toxicity at 14 days. Started Jan 2025; status: completed.
02
Drugs
JNJ-89853413
03
Conditions
acute myeloid leukemia (AML)myelodysplastic neoplasms (MDS)
Beyond the preview
Go deeper on NCT06618001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618001.